Business Wire

Ncardia Launches Custom CRISPR Gene Editing in hiPSC-Derived Cell Lines with Horizon Discovery as Strategic Partner

Del

Ncardia, a leader in human iPSC-based solutions for drug safety and efficacy screening, and Horizon Discovery Group plc (LSE:HZD) (Horizon), a global leader in gene editing and gene modulation technologies, announced a partnership to provide custom genetically modified and differentiated human iPSC-derived cells (hiPSC) for drug discovery researchers.

Drug discovery research requires rapid access to functional models of human disease. The new service from Ncardia enables disorders to be mimicked through introduction of genetic modifications in iPSC cell lines and subsequent differentiatiation into disease-relevant cell types, initially hiPSC-derived cardiomyocytes.

The partnership leverages Horizon’s experience in precision genome engineering to complement Ncardia’s expertise in manufacturing and differentiation of iPSC-derived cell lines. Under terms of the agreement, Ncardia will market and sell the products and services derived from the partnership. The companies see this service as an opportunity to increase accessibility of CRISPR-edited cell lines to researchers and provide clients with streamlined licensing and greater scientific value.

Johan te Koppele, Chief Services Officer, Ncardia, said: “Our aim is enable our clients to realize the full potential of disease modeling in drug discovery. Horizon’s leading position in CRISPR-Cas9 genome editing makes them an ideal partner in this unique service offering.”

Terry Pizzie, Chief Executive Officer, Horizon, commented: “The combination of genome engineering with iPSC-derived cell lines for disease modeling represents a powerful tool for researchers. Horizon is pleased to partner with Ncardia to enable better models and assays to advance human health.”

About Horizon:

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon’s platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalized molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company’s own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD.”

About Ncardia:

Ncardia (www.ncardia.com) is convinced that stem cell technology will help give patients faster access to better and safer medicines by improving the drug discovery and development process. The company develops and produces highly predictive human cellular assay systems for safety and efficacy testing of drug candidates. Ncardia is based in Belgium, the Netherlands, Germany and the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis.

www.ncardia.com

All product and company names herein may be trademarks of their registered owners.

Contact information

Ncardia
Dr Steven Dublin
Phone: +49 15 754743 427
info@ncardia.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AGCO Focuses on Animal Welfare17.1.2019 10:00Pressemelding

AGCO (NYSE: AGCO), a global leader in manufacturing and the distribution of agricultural equipment and solutions, today hosted its annual AGCO Berlin Summit. The international industry event aims to bring together decision-makers in politics, economy and society to share their experiences and discuss the future of the agricultural industry. Today’s ‘Feeding the World - The Future for Protein’ summit was focused on aspects of animal welfare in the context of modern agriculture, including the need for sustainable protein production to meet an increasing demand for protein-rich foods. The AGCO Berlin Summit is a joint initiative of AGCO and the new AGCO Agriculture Foundation. The AGCO Agriculture Foundation develops charitable initiatives to enhance global food security, sustainable agricultural development and positive economic impacts, particularly in developing countries. As in previous years, AGCO Finance and AGCO Fuse Technologies are sponsors of the 2019 AGCO Berlin Summit. "Whilst

Mr. Paul Bridwell Joins OpenGate Capital in Senior Operations Role for North America17.1.2019 08:00Pressemelding

OpenGate Capital, a global private equity firm, announced that Mr. Paul Bridwell joined the firm on November 5th, 2018, as Managing Director to lead operations and portfolio management for the firm’s North American-based investments. Based in Los Angeles, Bridwell joins the OpenGate senior leadership team as a member of the firm’s Investment and Portfolio Committees. Bridwell is a tenured professional with 15 years of private equity experience and has a proven track record of delivering operating results leading to superior investor returns. He possesses solid leadership and organizational skills both as portfolio company CEO and as an operations leader developed through his tenure at two global, private equity firms. Prior to joining OpenGate, Bridwell was Partner and Managing Director – Head of Operations at a major private equity investment firm in New York City, where he established the firm’s first operations-focused group and developed a comprehensive operations approach compatib

Anywhere365 Introduces Web Agent for Microsoft Dynamics 36517.1.2019 07:00Pressemelding

Workstreampeople, a global leader in contact center solutions for Skype for Business and Microsoft Teams, today announced the introduction of the Anywhere365 Web Agent for Microsoft Dynamics 365. Based on the Dynamics 365 Channel Integration Framework (CIF) the Web Agent is nested in the Dynamics 365 interface and provides users with Anywhere365’s omni-channel contact center functionality without having to move between applications. The Dynamics 365 client is automatically resized to accommodate the Web Agent ensuring none of the user interface is masked. Agents can receive, send, and automatically log calls, chats, emails and video all from within Dynamics 365, improving the efficiency and accuracy of customer interactions. From the Anywhere365 Web Agent, Dynamics 365 users can control media interactions and monitor real-time queue information. Integration with Microsoft Azure services provides automatic language detection and real-time translation of chat and voice interactions betwe

Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 201917.1.2019 06:30Pressemelding

Regulatory News: Results of the first in-human study of a recombinant neurotoxin are being presented at the TOXINS International Conference in Copenhagen. Ipsen’s recombinant BoNT serotype E (rBoNT-E) was investigated in a phase I study that demonstrated its safety and tolerability profile in healthy volunteers1. The study also reported that it has a faster onset of action and a shorter duration of effect, as well as a quick time to peak activity, in comparison with established BoNT-A products. Further studies will be initiated to establish potential aesthetic and therapeutic uses of this investigational therapy. “The application of recombinant techniques to create novel botulinum toxin-based medicines with different onsets and durations of action, will potentially offer clinicians the flexibility to choose the most appropriate neurotoxin for each patient, which is not an option today,” said Philippe Picaut, Pharm. D., PhD, Senior Vice President Research & Development for the Neuroscie

NTT Communications to Expand Ecosystem for Interconnection of Major Data Centers in Japan17.1.2019 03:04Pressemelding

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), announced today that it will expand the interconnection of its Nexcenter™ data centers in Tokyo and Osaka, Japan to enable client companies to connect with cloud and content services more flexibly than ever before. On a sequential basis from this month, NTT Com will begin directly connecting its ecosystem with three major internet exchanges (IXs) in Japan to enable clients to access services offered by these IXs and various NTT Com partner companies. Thereafter, NTT Com will continue to expand this ecosystem centered on NTT Com’s Nexcenter™ data centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005908/en/ Expanding Interconnection (Graphic: Business Wire) As a DX Enabler™, NTT Com uses ICT to achieve digital transformation (DX) "Transform and create business" together with clien

Piraeus Bank Presents the Principles for Responsible Banking with the Governor of the Bank of Greece16.1.2019 18:21Pressemelding

The Principles for Responsible Banking were presented today for the first time in Greece at an event organized by Piraeus Bank with Mr. Yannis Stournaras, the Governor of the Bank of Greece, as the keynote speaker. The event was organised as part of Piraeus Bank’s commitment to the United Nations Environment Programme Finance Initiative (UNEP FI). Piraeus is the only Greek bank to be a member of the global initiative, which includes twenty-eight banks from around the world, representing over USD 17 trillion in combined assets. Mr. Yannis Stournaras, the Governor of Bank of Greece, highlighted in his speech that the Bank of Greece fully supports the Principles for Responsible Banking and urges all of the banks to endorse the Principles and set ambitious targets. The Bank of Greece was one of the first central banks to become involved with the climate change issue, establishing the Climate Change Impacts Study Committee in 2009 and investing in one of the most significant Sustainable Dev